白血病干细胞

aoppolle

据美国物理学家组织网近日报道，一项新的研究成果表明，急性骨髓性白血病（AML）包含了一种具有干细胞特性的罕见细胞，称为“白血病干细胞”，它比一般的AML细胞能更好地预测临床结果。相关研究成果发表在最新一期出版的《自然·医学》杂志上。
/ I1 T/ x0 D; `' |
1 x$ M5 l' W6 W6 Q& o- \
, Z. C) Y8 i4 a. F( M2 C　　癌症科学家一直在争论，一个肿瘤中所有的细胞是具有相同作用还是某些癌细胞更具影响力，这在过去的10年里一直是实验模型所关注的重要问题。以往的异种移植研究也表明，一些实体瘤和白血病由肿瘤干细胞（CSCs）所维持的分级细胞组成，但对于肿瘤干细胞模型与病人的关系尚未明确。这是第一次揭示了白血病干细胞的临床重要性。
. s1 R9 u1 `& o( g0 @' j5 H; r3 E' w0 _. u
　　癌症干细胞领域的先驱者约翰·迪克领导的国际研究小组通过对健康的干细胞、白血病干细胞和临床资料进行排序、分析和比较，发现白血病干细胞拥有与正常干细胞同样的一组基因或特征，这可能有助于精准地预测患者的病程。这种干细胞特征表达强烈的病人，其剩余的生存时间比一般的病人会短些。
( o5 V( H$ N6 L! v# S
! a" H0 V, k& @0 h" H1 G　　这些干细胞信号中的基因提供了一种新的药物靶点，它能运用于消除白血病干细胞。这些基因同样显示了潜在的急性骨髓性白血病的生物标记，能够用于指导对病人施以更有效的治疗。从长期来看，这一信息还能用于将癌症治疗个性化，为病人提供合适的药物，而不是用现在放之四海而皆准的治疗方法，对成群的病人予以同样的治疗。+ U* X) y/ b% J: ^* k9 h! \/ t3 }: h
# B+ n" ~7 w6 w3 J
　　研究人员表示，该研究能够为实体瘤和各种白血病的癌症干细胞的临床重要性的测试提供一个范例，推动了整个癌症干细胞的研究。
; }9 |1 E2 B& J0 F8 z2 l( O9 C

jitianxing7021

我支持肿瘤干细胞，但是应和随机学说相结合！

naturalkillerce

回复 aoppolle 的帖子
' t; |9 L  r  v4 n9 s( ?3 x+ |- E! e. f! A
Clinical Importance of Leukemia Stem Cells Validated by New Study
/ g% b) |& q# y/ d) d
1 l" c  w4 p8 @# kScienceDaily (Aug. 28, 2011) — Cancer scientists have long debated whether all cells within a tumour are equal or whether some cancer cells are more potent -- a question that has been highly investigated in experimental models in the last decade. Research published in Nature Medicine focuses on patients and shows that acute myeloid leukemia (AML) contains rare cells with stem cell properties, called leukemia stem cells (LSC), that are better at predicting clinical outcome than the majority of AML cells, showing for the first time that LSCs are significant not just in experimental models but also in patients.: I( U% P& B# R  T) o

7 i+ ^# X( t' J+ z, N: h"Even though LSCs are like a needle in a haystack, their unique properties influence whether AML will respond to therapy or whether the disease comes back. This means that future efforts to prevent the disease from recurring and improving overall patient survival must consider ways to target LSCs to ensure they are killed," says principal investigator John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at the McEwen Centre for Regenerative Medicine and the Ontario Cancer Institute, Princess Margaret Hospital. Dr. Dick pioneered the cancer stem cell field by identifying leukemia stem cells in 1994 and colon cancer stem cells in 2007.
. K  G$ F/ Z; _' E9 G7 r4 q# y0 d# C) W' v( J- u
By sorting, analyzing and comparing healthy stem cells, leukemia stem cells and clinical data, Dr. Dick's international research team uncovered a set of genes, or signature, that was common to both normal and LSCs and showed that the set could accurately predict the course of disease in the patients studied. Patients that strongly expressed the stem cell signature had much shorter survival than those patients that had low expression of the signature. The research team included post-doctoral fellows Kolja Eppert, Eric Lechman and Katsuto Takenaka and PhD student Peter van Galen.( _8 g" M) U. `0 B
5 m0 \$ w$ x- q& O3 L
The genes within the stem cell signature provide new drug targets that could be used to eliminate LSCs. These genes also represent potential AML biomarkers that could be used to identify those patients that might benefit from more aggressive therapy. In the long term, this information could be used to personalize cancer therapy and get the right drug to the right patient, as opposed to a "one-size-fits-all" approach of treating groups of patients identically.
: t" F% A  s3 b; ~3 e7 q  [, Y- U# [9 q
"Although our research was on AML, our findings that LSCs are real and relevant in patients set the entire cancer stem cell field on a firmer footing. Our approach could be used as a template to test the clinical importance of cancer stem cells from solid tumors and other forms of leukemia," says Dr. Dick, who works out of UHN's Ontario Cancer Institute -- where stem-cell science began 50 years ago -- and alongside this generation's other leading stem-cell scientists at the McEwen Centre for Regenerative Medicine.
7 K  A  Q$ b% H6 t4 C+ k% f3 H
Dr. Dick recently isolated normal human blood stem cells and developed the first means to collect them in large quantities. As well as being a Senior Scientist at UHN's Princess Margaret and Toronto General Hospitals, he is a Professor in the Department of Molecular Genetics, University of Toronto, and Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research.9 I, u) q3 J7 p9 j7 p6 o' d4 e& b
0 y7 d. M* p5 |0 [) u
发表在Nature Medicine文献信息：, q9 \: O. ^4 @/ m# n% W
Kolja Eppert, Katsuto Takenaka, Eric R Lechman, Levi Waldron, Björn Nilsson, Peter van Galen, Klaus H Metzeler, Armando Poeppl, Vicki Ling, Joseph Beyene, Angelo J Canty, Jayne S Danska, Stefan K Bohlander, Christian Buske, Mark D Minden, Todd R Golub, Igor Jurisica, Benjamin L Ebert, John E Dick. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine, 2011; DOI: 10.1038/nm.2415，http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2415.html

yiyilinchuan

楼主辛苦啦

tianlanghehb

6 E; C' l# O: X& R( E, o6 T$ V3 Q/ @( p! V
事实上，至少在一种小鼠白血病模型上，白血病干细胞直接介导了肿瘤治疗的耐药性。